Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) rose 6.1% during trading on Wednesday . The stock traded as high as $22.18 and last traded at $22.18. Approximately 3,592 shares traded hands during trading, a decline of 97% from the average daily volume of 109,798 shares. The stock had previously closed at $20.90.
Analysts Set New Price Targets
VERA has been the subject of several research analyst reports. JPMorgan Chase & Co. started coverage on Vera Therapeutics in a research note on Tuesday, July 12th. They set an “overweight” rating and a $35.00 target price for the company. HC Wainwright boosted their price target on Vera Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, August 22nd.
Vera Therapeutics Stock Down 1.8 %
The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 0.04. The company has a fifty day simple moving average of $19.21 and a two-hundred day simple moving average of $18.54.
Insider Buying and Selling at Vera Therapeutics
Hedge Funds Weigh In On Vera Therapeutics
A number of institutional investors have recently modified their holdings of the business. Amalgamated Bank acquired a new position in Vera Therapeutics in the 1st quarter worth about $34,000. UBS Group AG acquired a new position in Vera Therapeutics in the 1st quarter worth about $47,000. Legal & General Group Plc increased its holdings in Vera Therapeutics by 274.8% in the 2nd quarter. Legal & General Group Plc now owns 4,898 shares of the company’s stock worth $67,000 after purchasing an additional 3,591 shares in the last quarter. American International Group Inc. increased its holdings in Vera Therapeutics by 29.2% in the 1st quarter. American International Group Inc. now owns 6,794 shares of the company’s stock worth $160,000 after purchasing an additional 1,535 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in Vera Therapeutics in the 1st quarter worth about $209,000. Institutional investors and hedge funds own 85.24% of the company’s stock.
About Vera Therapeutics
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
- Get a free copy of the StockNews.com research report on Vera Therapeutics (VERA)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.